• Tue news: Pfizer explores sale of hospital drugs unit. FDA declines full approval of Ocaliva. AZ better than expected Q3 results. Pfizer, Lilly telehealth platforms draw scrutiny. 23andMe cutting lays off 40%. See more on our front page

Amgen set to place bid on acquiring Medivation

Quote




It's now official Amgen is in the hunt for Medivation. We are going to kick their reps out and abuse them just like onyx. Hail to Sebastian Meyer and Jim Hassard.


http://www.bloomberg.com/news/artic...n-health-care-pack-weighing-medivation-offers

Amgen Inc. is considering a bid for Medivation Inc., joining a group of suitors circling the cancer therapy company, according to people with knowledge of the matter.

Amgen is speaking with advisers as it evaluates whether to make an offer, the people said, asking not to be identified because the deliberations are private. No final decision has been made, and Amgen may decide against moving forward, they said.
 












anonymous said:
David Piaquad close to putting in a bid for Medivation. McKinsey analysis and banking assumptions are what's holding up the bid.
Click to expand...

The model scenarios are built around the length of time Amgen will keep the existing Medivation team intact before transitioning to Amgen, including the Medivation sales force. The question is how long will it take Amgen OBU to be proficient to take over the Medivation team. From the onyx experience, the expectation is low retention from Medivation even with retention bonuses similar to what was given to
Onyx.

This is the type of
Asset Amgen will overpay since its on market and considered de-risked. Bob Bradway has issues with high valuations on non-derisked assets and would rather overpay then shift blame to commercial team for lack of making forecast vs. a program that failed in clinical development.

The OBU will have a new toy but it will be under intense scrutiny like kyprolis.
 




Word on the street is Amgen is looking at a $72 share price offer and willing to go up to $78 for the injection in revenue. The higher the price, more cost cutting will be needed to justify the acquisition.
 




anonymous said:
Word on the street is Amgen is looking at a $72 share price offer and willing to go up to $78 for the injection in revenue. The higher the price, more cost cutting will be needed to justify the acquisition.
Click to expand...

Wow. You must be really high up in the organization to be privy to a such confidential information. Thank you for sharing.
 




"From the onyx experience, the expectation is low retention from Medivation even with retention bonuses similar to what was given to Onyx. "

FYI, many Medivation employees are from Onyx. Fool them once.....

I'm a former Amgen employee and when Amgen announced that they were closing Onyx's buildings, my ED traveled from TO to Onyx and did a "Hail Mary" to try and convince his would-be employees to stay. No one did. Wonder whether he'd do it again if Amgen is the "winner."
 




anonymous said:
"From the onyx experience, the expectation is low retention from Medivation even with retention bonuses similar to what was given to Onyx. "

FYI, many Medivation employees are from Onyx. Fool them once.....

I'm a former Amgen employee and when Amgen announced that they were closing Onyx's buildings, my ED traveled from TO to Onyx and did a "Hail Mary" to try and convince his would-be employees to stay. No one did. Wonder whether he'd do it again if Amgen is the "winner."
Click to expand...


http://www.bidnessetc.com/68940-amgen-sanofi-desperate-medivation/

Amgen is the most desperate.

Medivation and everyone is the Bay knows of Amgens incompetence. None will stay long term for the abuse of Amgen
 




Amgen is waiting for Sanofi to replace the board then will try and outbid Pfizer and Sanofi for the company. Tony Hooper thinks Medivation is under optimized by CEO David Hung as he never had commercial experience and is learning on the job. The SF HQ location and rich benefits they offer employees is suboptimal and ripe for margin improvement.
 








anonymous said:
Amgen is waiting for Sanofi to replace the board then will try and outbid Pfizer and Sanofi for the company. Tony Hooper thinks Medivation is under optimized by CEO David Hung as he never had commercial experience and is learning on the job. The SF HQ location and rich benefits they offer employees is suboptimal and ripe for margin improvement.
Click to expand...

Sebastián Meyer and Jim Hassard have more commercial experience than George Hung.
They should be Medivation CEO.
 












Corlanor sucks , Blin barely sells, tvec doesn't sell, onyx doesn't sell enough to justify the 10.5B acquisition.

What do we do? Keep increasing the price of all decades old drugs.
 




Top Bottom
Back
Quote